Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints

Shares of Acceleron Pharma (NASDAQ: XLRN) shot up significantly in after-hours trading on Monday when the company announced positive results for its drug to treat pulmonary arterial hypertension (PAH). A phase 2 clinical trial of Acceleron's drug candidate, sotatercept, met both the primary and secondary endpoints of the trial.